Big Pharma has wrongly demonized HCQ because it’s off-patent, not a money maker. Vitamins A, C & D with zinc still work better, but Big Pharma rejects natural remedies. They didn’t even use zinc in many of their HCQ tests, which is what the docs were using when they got excellent, often immediate results!
Related:
Early on, it looked like the FDA would promote HCQ. Mike Rivero tells why not:
“There are cures out there. The American 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐚𝐫𝐞 𝐯𝐞𝐫𝐲 𝐮𝐩𝐬𝐞𝐭 𝐛𝐞𝐜𝐚𝐮𝐬𝐞 𝐚𝐥𝐥 𝐨𝐟 𝐭𝐡𝐞𝐬𝐞 𝐪𝐮𝐢𝐧𝐢𝐧𝐞 𝐝𝐞𝐫𝐢𝐯𝐚𝐭𝐢𝐯𝐞𝐬 𝐚𝐫𝐞 𝐯𝐞𝐫𝐲 𝐢𝐧𝐞𝐱𝐩𝐞𝐧𝐬𝐢𝐯𝐞. They use them in fish tank cleaner, by the way. … It’s an inexpensive chemical, and the pharmaceutical industries don’t like inexpensive cures. They want very expensive cures that they own. And that’s why we’ve had so many of our politicians, governors and mayors literally threatening doctors not to prescribe hydroxychloroquine and the others.”
“Apparently, the hydroxychloroquine prevents the cytokine storm that causes so much of the discomfort and the breathing problems, and the 𝐳𝐢𝐧𝐜 𝐤𝐢𝐥𝐥𝐬 𝐭𝐡𝐞 𝐯𝐢𝐫𝐮𝐬.”
– Mike Rivero on ‘What Really Happened,’ 3/30/20
History of HCQ studies
Sequential CQ / HCQ Research Papers and Reports
January to April 20, 2020
Executive Summary Interpretation of the Data In This Report
The HCQ-AZ combination, when started immediately after diagnosis, appears to be a safe and efficient treatment for COVID-19, with a mortality rate of 0.5%, in elderly patients. It avoids worsening and clears virus persistence and contagious infectivity in most cases.
– –
Hydroxychloroquine Has about 90 Percent Chance of Helping COVID-19 Patients
In a letter to Gov. Doug Ducey of Arizona, the Association of American Physicians and Surgeons (AAPS) presents a frequently updated table of studies that report results of treating COVID-19 with the anti-malaria drugs chloroquine (CQ) and hydroxychloroquine (HCQ, Plaquenil®).
To date, the total number of reported patients treated with HCQ, with or without zinc and the widely used antibiotic azithromycin, is 2,333, writes AAPS, in observational data from China, France, South Korea, Algeria, and the U.S. Of these, 2,137 or 91.6 percent improved clinically. There were 63 deaths, all but 11 in a single retrospective report from the Veterans Administration where the patients were severely ill.
The antiviral properties of these drugs have been studied since 2003. Particularly when combined with zinc, they hinder viral entry into cells and inhibit replication. They may also prevent overreaction by the immune system, which causes the cytokine storm responsible for much of the damage in severe cases, explains AAPS. HCQ is often very helpful in treating autoimmune diseases such as lupus and rheumatoid arthritis.
Additional benefits shown in some studies, AAPS states, is to decrease the number of days when a patient is contagious, reduce the need for ventilators, and shorten the time to clinical recovery.
Peer-reviewed studies published from January through April 20, 2020, provide clear and convincing evidence that HCQ may be beneficial in COVID-19, especially when used early, states AAPS. Unfortunately, although it is perfectly legal to prescribe drugs for new indications not on the label, the Food and Drug Administration (FDA) has recommended that CQ and HCQ should be used for COVID-19 only in hospitalized patients in the setting of a clinical study if available. Most states are making it difficult for physicians to prescribe or pharmacists to dispense these medications.
Leave a Reply